For instance, the HLA class II molecule HLA-DRA has been identified as a marker for immuno-hot tumors, predicting therapeutic responses to anti-PD-1 immunotherapy in NSCLC [290]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.